Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and PK Study of Evening Dosed Methylphenidate Hydrochloride ER Capsules (HLD200) in Children Aged 4-5 Years With ADHD

NCT06431256 is registered in ClinicalTrials.gov with Ironshore Pharmaceuticals and Development, Inc as lead sponsor.

NCT NCT06431256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06431256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and PK Study of Evening Dosed Methylphenidate Hydrochloride ER Capsules (HLD200) in Children Aged 4-5 Years With ADHD
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Phase
Phase 3
Overall status
Terminated
Start date
September 13, 2024
Completion date
July 11, 2025
Enrollment
26 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder